Steve's verdict on a 'cloudy downgrade' from THL | 4D Medical's momentum
About this video
There's a medical theme going on the 'small caps' latetly. We're talking to two CEOs, one in imaging software, and another in diagnostics. We had Steve Johnson from Forager Funds Management ready to spill the beans on some market insights. Steve's got his eyes on tourism holdings (THL), which took a bit of a hit today. Don't worry, though, he's still a believer in the long-term story.
Yesterday we spoke to Henry Jennings about a small cap stock he had his eye on. 4DMedical (4DX), the lung imaging software company is in the market for fresh funds, looking to raise $35 million via a share purchase plan at 91 cents per share. Today we had 4DMedical's CEO Andreas Fouras joining us to tell more about the company's performance.
And a new breast cancer blood screening tool by an Aussie Bio-tech company BCAL diagnostics (BDX) is set to change the future of early detection. BCAL is still looking for more blood samples from a wide cross section of ethnicity, age and health status, to participate in the ongoing development of its blood screening innovation. You can register your interest online at www.bcaldiagnostics.com. BCAL's executive Chair, Jayne Shaw joined us live in the studio to tell more.